Actelion’s PAH drug fails to hit target in PhIII study
Actelion has suffered a setback in its quest to expand the uses of Tracleer follow-up Opsumit, after a study assessing the drug in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger Syndrome failed to meet its primary goal.
Read More
